Financial Review: Bausch + Lomb (NYSE:BLCO) & IceCure Medical (NASDAQ:ICCM)

Bausch + Lomb (NYSE:BLCO – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for Bausch + Lomb and IceCure Medical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch + Lomb 1 8 4 2 2.47
IceCure Medical 1 1 2 0 2.25

Bausch + Lomb currently has a consensus target price of $20.83, suggesting a potential downside of 1.61%. IceCure Medical has a consensus target price of $30.00, suggesting a potential upside of 3,926.85%. Given IceCure Medical’s higher probable upside, analysts plainly believe IceCure Medical is more favorable than Bausch + Lomb.

Profitability

This table compares Bausch + Lomb and IceCure Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bausch + Lomb -2.05% 5.01% 2.34%
IceCure Medical -427.67% -174.26% -112.58%

Insider and Institutional Ownership

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Bausch + Lomb and IceCure Medical”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bausch + Lomb $5.42 billion 1.40 -$360.00 million ($0.31) -68.31
IceCure Medical $3.95 million 0.65 -$15.06 million ($8.52) -0.09

IceCure Medical has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Bausch + Lomb has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.

Summary

Bausch + Lomb beats IceCure Medical on 10 of the 15 factors compared between the two stocks.

About Bausch + Lomb

(Get Free Report)

Bausch + Lomb Corporation is an eye-health company that develops, manufactures and markets products for consumers, eye-care professionals and surgical teams. Its business spans vision care, pharmaceuticals and surgical devices. Its products include contact lenses and lens-care solutions, as well as eye-health medicines and nutritional supplements. The company also supplies equipment, technologies and related products used in eye surgery and other ophthalmic procedures. Founded in Rochester, New York, in 1853 by John Jacob Bausch and Henry Lomb, the company serves customers in more than 100 countries.

About IceCure Medical

(Get Free Report)

IceCure Medical Ltd. is an Israel-based medical technology company that develops and commercializes minimally invasive cryoablation systems. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, offering a percutaneous approach to treating tumors. The company’s ProSense system is designed for image-guided cryoablation and is used in procedures involving breast, kidney, lung, bone and other tumors. IceCure also offers the IceSense3 system for treating benign breast fibroadenomas.

Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.